Evidence map›Paper›PMID 40647544›Full record

ReviewCancers2025

Is [

Francesco Fiorica, Maria Viviana Candela, Teodoro Sava, Matteo Salgarello, Jacopo Giuliani, Singh Navdeep, Antonella Franceschetto, Daniela Grigolato, Emilia Durante, Erica Palesandro and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Francesco FioricaDepartment of Clinical Oncology, Section of Radiation Oncology and Nuclear Medicine, AULSS 9 Scaligera, 37122 Verona, Italy.ORCID 0000-0002-9404-3655
Maria Viviana CandelaBusiness and Law, High School of Sciences, Liceo Scientifico Antonio Roiti, 44121 Ferrara, Italy.
Teodoro SavaDepartment of Clinical Oncology, Section of Medical Oncology, AULSS 9 Scaligera, 37122 Verona, Italy.
Matteo SalgarelloNuclear Medicine Unit, Ospedale Sacro Cuore Don Calabria Istituto di Ricovero e Cura a Carattere Scientifico, 37024 Negrar di Valpolicella, Italy.
Jacopo GiulianiDepartment of Clinical Oncology, Section of Medical Oncology, AULSS 9 Scaligera, 37122 Verona, Italy.ORCID 0000-0003-4096-2514
Singh NavdeepDepartment of Clinical Oncology, Section of Radiation Oncology and Nuclear Medicine, AULSS 9 Scaligera, 37122 Verona, Italy.ORCID 0000-0001-9290-6448
Antonella FranceschettoDepartment of Clinical Oncology, Section of Radiation Oncology and Nuclear Medicine, AULSS 9 Scaligera, 37122 Verona, Italy.
Daniela GrigolatoNuclear Medicine Unit, Ospedale Sacro Cuore Don Calabria Istituto di Ricovero e Cura a Carattere Scientifico, 37024 Negrar di Valpolicella, Italy.
Emilia DuranteDepartment of Clinical Oncology, Section of Medical Oncology, AULSS 9 Scaligera, 37122 Verona, Italy.
Erica PalesandroOncology Unit, Agnelli Hospital, 10064 Turin, Italy.
Enrico Altiero GiustoDepartment of Medical Sciences, Section of Experimental Medicine, Laboratory for Technology of Advanced Therapies, University of Ferrara, 44121 Ferrara, Italy.ORCID 0009-0001-8430-337X
Consuelo ButtiglieroDepartment of Oncology, San Luigi Gonzaga Hospital, University of Turin, 10043 Orbassano, Italy.ORCID 0000-0002-2877-2518
Marcello TucciDepartment of Oncology, Cardinal Massaia Hospital, 14100 Asti, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadioligand therapy with [

objectiveTo compare overall survival (OS), radiographic progression-free survival (rPFS), PSA response, and treatment burden across randomised trials evaluating [ EVIDENCE ACQUISITION: We conducted a meta-analysis of five randomised controlled trials, including 2073 patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). We assessed survival endpoints, baseline comparability, and treatment intensity. EVIDENCE SYNTHESIS: [

conclusions[ PATIENT SUMMARY: This study suggests that PSMA-targeted radioligand therapy is at least as effective as other treatments for advanced prostate cancer, with potential benefits in terms of toxicity, duration, and overall cost.

Indexed as

[177Lu]Lu-PSMA-617 and mCRPCCost-effectiveness radioligand therapyEconomics evaluation [177Lu]Lu-PSMA-617PSMA-targeted therapy

Identifiers

PMID40647544
PMCPMC12248729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.